{"id":390510,"date":"2018-12-24T00:00:00","date_gmt":"2018-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2018-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2018\/"},"modified":"2026-04-29T05:25:18","modified_gmt":"2026-04-29T05:25:18","slug":"dlsfon0015-2018-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2018-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2018\/","title":{"rendered":"Gastroesophageal Cancer | Disease Landscape &#038; Forecast | G7 | 2018"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and\u00a0<abbr title=\"gastroesophageal junction\">GEJ<\/abbr>\u00a0adenocarcinoma in the major pharmaceutical markets under study, and neither agent is approved to treat esophageal cancer. Roche\/Genentech\/Chugai\u2019s Herceptin is the first-line standard of care for\u00a0<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-positive metastatic patients, and Eli Lilly\u2019s Cyramza is approved for patients with advanced disease following fluoropyrimidine- and platinum-based therapy. Additionally, two\u00a0<abbr title=\"programmed cell death-1\">PD-1<\/abbr>\u00a0inhibitors\u2014Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s Opdivo (Japan only) and Merck &#038; Co.\u2019s Keytruda (United States only)\u2014are approved to treat third- and later-line gastric and\u00a0<abbr title=\"gastroesophageal junction\">GEJ<\/abbr>adenocarcinoma. Despite these approvals, the gastroesophageal cancer therapy market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; agents span a range of drug classes and target various gastroesophageal cancer populations associated with significant unmet need. These treatments may soon offer patients a more-optimistic outlook.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How do current treatment practices differ between esophageal, gastric, and\u00a0<abbr title=\"gastroesophageal junction\">GEJ<\/abbr>cancer, and which populations provide the greatest drug-treatment opportunities by geography?<\/li>\n<li>What are interviewed thought leaders\u2019 insights on Herceptin, Cyramza, Keytruda, Opdivo, and chemotherapy? What clinical needs remain unfulfilled, and on which opportunities can developers capitalize?<\/li>\n<li>Which other immune checkpoint inhibitors (Bavencio, Yervoy, tislelizumab) are expected to be approved and in which disease setting(s), and how will they compete with currently marketed and established therapies?<\/li>\n<li>What agents with novel mechanisms of action are being assessed in Phase III trials, which populations are they targeting, and how will they impact the gastroesophageal cancer therapy market?<\/li>\n<li>What are the market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast:<\/em>\u00a0Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390510","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390510\/revisions"}],"predecessor-version":[{"id":576662,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390510\/revisions\/576662"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}